Company: PMVP
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001193125-25-137497
Chunk: 0

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07.      Submission of Matters to a Vote of Security Holders.  

On June 5, 2025, PMV Pharmaceuticals, Inc. (the “ Company”) held its virtual 2025 Annual Meeting of Stockholders (the “ Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:

Proposal 1. Election of Directors

The Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2028 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows:

                                      FOR                      WITHHELD                      BROKER                   
                                                                                             NON-VOTE                 
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Arnold Levine, Ph. D.                        26,723,192                     5,118,916                    8,760,485  
  Charles M. Baum, M. D., Ph. D.               13,258,337                    18,583,771                    8,760,485  

Proposal 2. Non-Binding

On a non-bindingadvisory basis, the compensation paid to the Company’s named executive officers as described in its definitive proxy statement on Schedule 14A, filed with the U. S. Securities and Exchange Commission (the “ SEC”) on April 25, 2025 (the “ Proxy Statement”), was not approved by the Company’s stockholders. The final voting results are as follows:

         FOR         AGAINST      ABSTAIN         BROKER  
                                                NON-VOTE  
 ──────────────────────────────────────────────────────────
  11,646,401      20,170,398       25,309      8,760,485  

Consistent with the recommendation of the Company’s Board of Directors and based on the Company’s stockholders’ approval at the Company’s 2022 annual meeting of stockholders, held on June 2, 2022, the Company conducts non-bindingadvisory votes on the compensation of its named executive officers every year. This policy will remain in effect until the next non-bindingadvisory stockholder vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers, expected to be held at the Company’s 2028 annual meeting of stock